据了解，TCR-T是一种通过基因工程技术改造患者自身T细胞，使其特异性识别并杀伤肿瘤细胞的免疫 治疗方法，相较于市场更为熟知的CAR-T疗法在有效性及安全性上均显示出更好的潜力。2024年7月， 公司在研1类新药TAEST16001注射液作为国内首个获得IND批准的TCR-T细胞治疗药物，用于晚期软组 织肉瘤适应症治疗已被CDE纳入突破性治疗品种名单。中报披露，该适应症目前已正式进入确证性临床 试验阶段。若产品后续研发顺利开展并获批上市，有望推动我国细胞治疗水平的提升，帮助香雪制药确 立在免疫细胞治疗领域的行业地位。 更进一步，中报披露，目前子公司香雪生命科学已获得五个关于TCR-T产品的《临床试验通知书》，其 中，TAEST16001注射液已获得三个，适应症分别为晚期软组织肉瘤、晚期食管癌、晚期非小细胞肺 癌。TAEST1901注射液获得两个，适应症为原发性肝癌、晚期胃癌。在该领域，公司已搭建起具有国 际领先水平的前沿生物技术医药研发基地和转化平台，建立起TCR-T完整的技术平台及工艺。 与此同时，公司传统中成药产品仍具备产品及品牌优势。中报指出，香雪抗病毒口服液为全国首个完成 上市后感冒症状随机双盲安慰剂 ...

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]